Xbrane Biopharma delivers first batch of Spherotide to a value of 7 MSEK
Xbrane Biopharma has delivered its first batch of Spherotide to its partner in the Middle East to a […]
OrganoClicks subsidiary BIOkleen signs general agreement with Granngården
OrganoClicks subsidiary, BIOkleen Miljökemi AB, sells and markets cleaning and maintenance products for wood, home, house, and automotive. […]
Outcome of Episurf Medical’s rights issue
The subscription period for Episurf Medical’s new issue of A and B shares with preferential right for the […]
Episurf Medical AB to present at Aktiedagen, held in Stockholm on March 6
Episurf Medical AB will present at Aktiedagen, an investor conference held in Stockholm (Operaterassen, Karl XII:s torg) on […]
At Serendipity, we are proud of our heritage and we embrace our serendipitous beginnings. So much so, that it is a fundamental element in our philosophy and the way we work.
For more than a decade, Serendipity has focused on transforming cutting edge technologies into products and services that bring value to the world. Ranging from environmentally friendly alternatives to existing products to novel products that pave the way and set new standards in their respective fields, we seek to build sustainable businesses with global markets.
Net Asset Value per Share
Net Asset Value
Informations- och uppdateringsseminarium 19 april 2017
Varmt välkommen till Serendipity Ixoras informations- och uppdateringsseminarium som äger rum onsdagen den 19 april 2017. Platsen för seminariet är […]
Varmt välkommen till Serendipity Ixoras årsstämma 2017. Datum: Onsdagen den 7 juni 2017 För mer information vänligen kontakta: Amin […]
Informations- och uppdateringsseminarium 1 december 2016
Varmt välkommen till Serendipity Ixoras informations- och uppdateringsseminarium som äger rum torsdagen den 1 december 2016. Platsen för […]
We identify, develop, and invest in leading innovative technologies and companies with the ability to make global impact on societal and industrial grand challenges. As such, our portfolio companies combine disruptive technologies and trends with strong and competent teams aiming for global markets.
Each new investment is evaluated in terms of market potential, scalability, distinct competitive advantage, high differentiation, strong leadership, and the ability to deliver high margins over time.
We build to keep. Therefore we have no explicit exit strategy, provided that the company continues to generate growth in line with our targets.